Here are nine new drug shortages and discontinuations, according to drug supply databases from the FDA and the American Society of Health-System Pharmacists.
- Dextroamphetamine extended-release capsules: Teva has reported a shortage of dextroamphetamine sulfate extended-release capsules, a central nervous system stimulant used to treat ADHD and narcolepsy in 5-, 10- and 15-milligram presentations. No reason was provided for the shortage and Amneal’s Dexedrine Spansule capsules are available as alternatives.
- Ethionamide tablet: Pfizer has discontinued the manufacture of Trecator 250 milligram tablets, an anti-infective drug used in the treatment of tuberculosis. Supply is expected to last until September 2025.
- Insulin aspart injection: Novo Nordisk will discontinue unbranded insulin aspart injection products including FlexPen pens, PenFill cartridges and 10-milliliter vials by Dec. 31, 2025. Insulin aspart is a rapid-acting insulin used to control blood sugar in diabetes patients.
- Insulin aspart protamine and insulin aspart mix 70/30 injectable suspension: Novo Nordisk is discontinuing unbranded insulin aspart protamine and insulin aspart mix 70/30, a combination insulin product used for blood sugar control in diabetes by Dec. 31, 2025.
- Insulin degludec injection: Novo Nordisk plans to fully discontinue unbranded insulin degludec injections including U-100 and U-200 FlexTouch pens and 10-milliliter vials by Dec. 31, 2025. Insulin degludec is a long-acting basal insulin used for diabetes management.
- Lidocaine patch: Actavis Pharma has discontinued the NovaPlus label of the 5% lidocaine patch used for localized pain relief, including neuropathic pain and post-herpetic neuralgia.
- Oxaprozin tablet: Hospira has discontinued Daypro 600-milligram tablets, a nonsteroidal anti-inflammatory drug used to treat pain and inflammation associated with arthritis.
- Pemetrexed ditromethamine injection: Pfizer has discontinued the manufacture of pemetrexed ditromethamine injection in 100- and 500-milligram single-dose vials, an oncology drug used to treat various cancers, including non-small-cell lung cancer and mesothelioma.
- Potassium citrate tablet, extended release: Watson Pharma Private Limited has discontinued all extended-release potassium citrate tablets in 5-, 10- and 15-milliequivalent presentations, which are used to prevent kidney stones and treat some metabolic conditions. The discontinuation was due to a business decision.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.